首页 / 院系成果 / 成果详情页

Concordance of immunohistochemistry and fluorescent in situ hybridization for anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer: results from a multicenter study in China 期刊论文

编号：

9f1a807e-7121-4972-ba5f-b7ea080fbe14
作者：

Sun, Yu^[1];Yang, Fei(杨飞)^[2]Zhou, XiaoYan(周晓燕)^[2,4,5]Zhou, LiXin^[1];Li, XiangHong^[1];Lv, Ning^[3];Ying, JianMing^[3];Du, Xiang(杜祥)*^[2,4,5,6]
语种：

English
期刊：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE ISSN：1940-5901 2016 年 9 卷 2 期 (2642 - 2653)
收录：
关键词：

Non-small cell lung cancer EML4-ALK gene fusion immunohistochemistry fluorescent in situ hybridization
摘要：

Crizotinib, a small molecular anaplastic lymphoma kinase (ALK) inhibitor, was approved by the Chinese Food and Drug Administration for ALK positive non-small cell lung cancer (NSCLC) patients in 2013. Although clinical trials have used the Vysis fluorescent in situ hybridization (FISH) ALK Break-Apart Assay to determine ALK status, the test is only available in limited laboratories and is technically challenging. A standardized and cost effective methodology is therefore in high demand. The aim of this study was to compare the diagnostic accuracy of Vysis FISH ALK Break-Apart Assay and VENTANA ALK (D5F3) immunohistochemistry (IHC) assay for detection of echinoderm microtubule associated protein like4-anaplastic lymphoma kinase (EML4-ALK) rearrangement in NSCLC. FISH and IHC analyses were performed on 1174 cases collected from three provincial cancer hospitals in China. The patient cohort included cases of NSCLC, small cell lung cancer (SCLC), normal lung specimens and other tumor types. We found that IHC assay is highly concordance with FISH assay, showing a positive percent agreement rate of 99.30%, negative percent agreement rate of 99.22%, and overall agreement rate of 99.23%. Our results thus suggest that the VENTANA ALK (D5F3) IHC assay is a valuable tool for the screening of patients with ALK rearrangement in clinical practice.
推荐引用方式
GB/T 7714：

Sun Yu,Yang Fei,Zhou Xiao-Yan, et al. Concordance of immunohistochemistry and fluorescent in situ hybridization for anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer: results from a multicenter study in China [J].INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE,2016,9(2):2642-2653.
APA：

Sun Yu,Yang Fei,Zhou Xiao-Yan,Zhou Li-Xin,&Du Xiang.(2016).Concordance of immunohistochemistry and fluorescent in situ hybridization for anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer: results from a multicenter study in China .INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE,9(2):2642-2653.
MLA：

Sun Yu, et al. "Concordance of immunohistochemistry and fluorescent in situ hybridization for anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer: results from a multicenter study in China" .INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE 9,2(2016):2642-2653.

浏览次数：13  下载次数：0

分享到：

浏览次数：13

下载次数：0

打印次数：0